Articles On Orthocell (ASX:OCC)

Orthocell Ltd (ASX: OCC) shares are catching the eye again on Tuesday. In morning trade, the ASX healthcare stock is up 11% to $1.53. This means that the regenerative medicine company's shares are now up 290% since this time last year. To p...

New Hope Corporation Ltd (ASX: NHC) shares are on the move on Tuesday morning. At the time of writing, the coal miner's shares are up 8% to $3.99. This follows the release of its half year results before the market open. New Hope shares jum...

The iShares Core S&P/ASX 200 ETF (ASX: IOZ) has gone through a dip in the last few weeks as the global share market has suffered from worries about a trade war between the US and various countries. As the chart above shows, the IO...

Orthocell Ltd (ASX: OCC) share price is catching the eye of investors on Monday. In late afternoon trade, the regenerative medicine company's shares are up over 10% to $1.37. This means that Orthocell shares are now up approximately 250% si...

The S&P/ASX 200 Health Care Index fell 7.66% in February with the S&P/ASX 200 down 3.79% Morgans healthcare analyst Iain Wilkie said several factors caused investor jitters in February including job cuts to US FDA  Pacific Edge was...

Highlights Several ASX-listed biotech companies are nearing FDA approval, signifying potential entry into the crucial U.S. market. The FDA has improved its communication with applicants, fostering a more predictable approval process....

Having lodged their paperwork, companies including EBR Systems, Artyra and Orthocell await crucial FDA approval The agency has improved its communications with applicants, which avoids nasty surprises Applicants are doing the commercial gr...

Highlights: Fisher & Paykel Healthcare (ASX:FPH) faces new tariffs but is adapting with strategic measures. Orthocell (ASX:OCC) is progressing with regulatory approvals in multiple markets. Life-sciences...

Telix Pharmaceuticals (ASX:TLX) has joined a somewhat quiet cohort of ASX biotech companies having a pretty good run lately, in some cases outperforming just about everything else. (Just think: Mesoblast, Orthocell, Clarity Pharmaceutica...

Clarity Pharmaceuticals (ASX:CU6) has seen the U.S. FDA fast-track its prostate cancer imaging compound for use in PET scans on patients with recurring prostate cancer. The stock jumped 4% in the first hour of trade to $4.23 in what is...

  Early sales transaction has been achieved for Remplir across major jurisdictions A global expansion is underway to increase revenue opportunities The company is planning to broaden its commercial footprint in existing and new markets...

The ASX200 closed up 0.33% at 8,429 points. This was a seven-week closing high, achieved amidst positive sentiment as investors react to Donald Trump’s “Stargate” plan for AI investment, and an initially better than expected trade outcom...

ASX climbs as tech stocks lead the charge Trump’s $500b AI plan boosts tech stocks Tariff talk sparks gains for uranium stocks, losses for iron ore miners   Wednesday saw another climb for the Aussie stock market as the S&P/ASX 200 in...

WA biotech Orthocell will accelerate plans to enter five new markets this year, buoyed by the early sales traction recorded in Australia, New Zealand and Singapore for its flagship nerve repair product.

Pacific Edge flags a legal challenge to a ruling that excludes its bladder cancer test from US public reimbursement ‘Pfizer Riser’ challenger LTR Pharma readies for Australian approval with a national distribution deal Nerve-repair house O...

Highlights  ASX poised to climb as US markets rally overnight.  US tech and healthcare stocks shine, bolstering sentiment.  Oil prices slide as energy policies raise output concerns.  The Australian stock market is set for another...

ASX edges up, Trump’s return on the radar Bitcoin dips after hitting $106k, Star Entertainment Group tanks Banks push ASX higher, Karoon Energy struggles   The ASX saw a small but steady rise on Monday, up 0.45% as traders nervously eyed...

ASX up again after surprise inflation spike Miners led gains as financials rode rate bet Energy Transition Minerals soared on Trump talk   The ASX kept its momentum rolling, up 0.77% on Wednesday as an inflation report surprise gave the R...

Wound care company Avita Medical slumps ~19% on downgrade of its earnings guidance Infection-control medtech Next Science hit with legal action by a former employee Biotech Orthocell achieves third consecutive quarter of record revenue  ...

Orthocell achieves third consecutive quarter of record revenue, reporting $2.21 million in Q2 FY25 Growth attributed to increase in sales of its Striate+ and Remplir products Regulatory approval of Remplir in US expected in March/April 202...

Highlights:  ASX 200 Futures indicate a cautious start with a focus on upcoming inflation data from the ABS.  Global markets faced declines, with US indices reversing gains and European markets showing mixed performances.  Commodities...

The S&P/ASX 200 Health Care Index fell 1.85% in December but rose 7.51% overall in 2024  Mesoblast surged 52% in December after the US FDA approved its cell therapy Ryoncil for treatment of paediatric GvHD Percheron plunged 91% in Dece...

The S&P/ASX 200 fell 3% in December as Santa rally failed to eventuate yet again  Consumer staples led the S&P/ASX 200 sectors in December with tech leading overall in 2024 Niobium and rare earths explorer Aldoro Resources led the...

Having raised cash from the likes of Chris Ellison, Rod Jones, the McCusker family and Chris Judd, the fast-running biotech stock has been among the ASX’s best performers over the past six weeks.

From artificial intelligence (A.I) to zygotes, the biotech sector this year delivered the A to Z of excitement, intrigue, occasional disappointment and downright disaster. His virtual stethoscope on hand, Dr Boreham was on duty to diagnose...

WA biotech Orthocell has started selling its nerve repair product in Singapore, two months after the company received regulatory approval in the country.

The ASX200 closed down 0.28% at 8,330 points – finishing the session at a three-week low. Jobs data today surprised analysts, with unemployment falling to 3.9%. Now the odds of an early interest rate cut have lengthened, and the Aussie d...

Key Highlights:  Strong Global Market Performance: US and European markets show robust growth, with the Nasdaq hitting a new all-time high. The S&P 500 and European aerospace stocks also saw notable gains, setting a positive tone fo...

Orthocell (ASX:OCC) has achieved first sales of its peripheral nerve repair product Remplir in Singapore. This marks an early milestone ahead of a previously planned launch in the first quarter of 2025. Remplir is made from a collagen-based...

On Chris Judd’s Talk Ya Book today, the AFL legend sat down with Orthocell Limited (ASX:OCC) chairman John Van Der Wielen to talk about the “overnight success” of the ASX-listed biotech company and its bright future. “We wanted to start...

The S&P/ASX 200 Health Care Index rose 2.89% in November as momentum returned to the sector Health cryogenic services company Vitrafy and nerve-repair biotech Renerve debuted on the ASX  Paradigm Biopharmaceuticals rose 151% in Novembe...

ASX loses momentum after near-record high Tech stocks lead, but CSL falls; retail sales rise 0.6% in October Northern Star to buy De Grey for $5 billion   The ASX has lost some of its early momentum today, pulling back from a record high...

Orthocell (ASX:OCC), has risen more than 7% today after clearing the latest hurdle to distributing its nerve repair product in the U.S. The stock’s bull run over the last two months has seen its share price more than double as investors eye...

Stockhead’s Break it Down brings you today’s leading market news in under 90 seconds. In this episode, host Sarah Hughan tells all on Orthocell’s (ASX:OCC) nerve repair product deemed safe and effective for use in the surgical repair of per...

Orthocell US FDA 510(k) regulatory study of peripheral nerve-repair product Remplir meets all endpoints Company due to submit 510(k) application in December with US FDA approval expected in Q1 CY25 Study found use of Remplir results in hig...

“Outstanding” pivotal trial results paves the way for Orthocell to seek US approval for its Remplir nerve wrap Percheron promises Duchenne trial results by Christmas Argent Biopharma says it’s not goodbye – or au revoir   Orthocell (ASX:O...

Orthocell (ASX:OCC), a Perth-based regenerative medicine company, has successfully completed a pivotal US FDA 510(k) regulatory study for its nerve repair product, Remplir. The study validated Remplir as safe and effective for use in the su...

Orthocell Ltd (ASX: OCC) shares are starting the week with a very big bang. In morning trade, the ASX healthcare share is up 26% to a 52-week high of $1.02. Why is the ASX healthcare share soaring today? Investors have been fighting to get...

Breaking Out is a technical analysis-fuelled, short ‘n’ sharp take on chart-busting ASX stocks. Each week, Steve Collette – head of Collette Capital in Melbourne – narrows in on something that’s caught his eye.   Orthocell (ASX:OCC) Orthoce...

Highlights ASX 300 showcases top movers with significant percentage changes across sectors. Consumer Discretionary and Telecommunications drive market gains amid stable sentiment. ASX mining and energy stocks experience mixed outcomes...

Highlights Web Travel Group WEB shares rise 13.48% following strong TTV growth. Pinnacle Investment Management PNI declines after announcing $25M SPP. ASX rebounds, with all sectors closing in positive territory. The Australian sh...

ASX rises on rally across the board Israel and Hezbollah agree to 60-day ceasefire City Chic tumbles after downbeat update   The Aussie share market enjoyed a solid ride on Wednesday, driven by a broad rally as optimism from Wall Street’s...

Stockhead’s Break it Down brings you today’s leading market news in under 90 seconds. In this episode, host Sarah Hughan tells all on Orthocell’s (ASX:OCC) medical device sales in Singapore on the appointment of an exclusive distributor. It...

Orthocell (ASX:OCC) has appointed Device Technologies Asia (DVT Asia) as the exclusive distributor of its nerve repair device, Remplir, in Singapore. This marks the product's first major international expansion beyond Australia and New Zeal...

Orthocell appoints Device Technologies Asia as exclusive distributor of nerve repair product Remplir in Singapore Device Technologies has been credited with driving rapid sales of Remplir in Australia and New Zealand Orthocell said market...

Nerve-repair company Renerve is set to make its ASX debut today Renerve is developing products for repair and replacement of damaged peripheral nerves It becomes only the second nerve-repair company on the ASX, after Orthocell   When Rene...

Stockhead’s Sarah Hughan sits down with Orthocell (ASX:OCC) chairman John Van Der Wielen to get the short end of the long story on the company’s latest news. The regenerative medicine company has appointed two US-based executives to drive t...

Botanix has FDA approval for its treatment for hyperhidrosis, or excessive sweating Sufferers have not had an effective treatment for the socially debilitating disorder Broker E&P Financial Group estimates revenues of close to $100 mil...

ASX healthcare stocks underperform but optimism grows Uscom, Respiri and Hitiq report mixed results Artrya and Nyrada make key clinical advances   The S&P/ASX 200 Health Care [XHJ] index was down 0.9% gain in October. For the year, th...

Orthocell (ASX:OCC) has secured $17m in a recent capital raising initiative, aimed at funding the US launch of its flagship Remplir device. The funds will also support expansion into Singapore, Southeast Asia, and Europe, and be allocated t...